Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.The Motley Fool • 08/09/26
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare ConferenceBusiness Wire • 08/04/26
4 Non-Tech Stocks to Grab as Dow Hits New Milestone Amid AI Sell-offZacks Investment Research • 08/04/26
Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective SeptemberBusiness Wire • 08/04/26
Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System TranscriptSeeking Alpha • 08/03/26
Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?Zacks Investment Research • 08/03/26
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 07/31/26
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology PipelineBenzinga • 07/31/26
Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited AboutThe Motley Fool • 07/30/26
Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech DealsBenzinga • 07/30/26
Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 07/30/26
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerPRNewsWire • 07/30/26
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology InnovationBusiness Wire • 07/29/26